Nimbus clinches $125M raise via big donor-backed private financing round following Bristol Myers' TYK2 approval
More than a year after raising $105 million in a private financing round, Nimbus Therapeutics is back with its next haul as it considers its next steps, thanks to Bristol Myers Squibb.
The computational chemistry biotech, co-founded in 2009 by VC Bruce Booth, announced its most recent financing round Monday worth $125 million — Nimbus’ fifth big financing in the last seven years.
CEO Jeb Keiper tells Endpoints News that the financing will support Nimbus’ entire pipeline, including its lead candidates and preclinical efforts. At the biotech’s forefront is its TYK2 program, which is currently in a Phase IIb study for psoriasis. And according to Keiper, the biotech is running hot in its attempt to get its TYK2 drug past the regulatory finish line — courtesy of Bristol Myers beating them to the punch with its own TYK2 drug just last week, now branded as Sotyktu, for psoriasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.